Click here to load reader

Roche YTD September 2017 sales 2b154838-34d9-4f35-9c49-336a96a94c91/...Japan International Europe US Diagnostics ... -250 -150 -50 50 150 250 350 450 ... (adjuvant setting); HR=hormone

  • View
    237

  • Download
    11

Embed Size (px)

Text of Roche YTD September 2017 sales 2b154838-34d9-4f35-9c49-336a96a94c91/...Japan International Europe US...

  • Roche

    YTD September 2017 sales

    Basel, 19 October 2017

  • 3

    This presentation contains certain forward-looking statements. These forward-looking

    statements may be identified by words such as believes, expects, anticipates, projects,

    intends, should, seeks, estimates, future or similar expressions or by discussion of, among

    other things, strategy, goals, plans or intentions. Various factors may cause actual results to

    differ materially in the future from those reflected in forward-looking statements contained in

    this presentation, among others:

    1 pricing and product initiatives of competitors;

    2 legislative and regulatory developments and economic conditions;

    3 delay or inability in obtaining regulatory approvals or bringing products to market;

    4 fluctuations in currency exchange rates and general financial market conditions;

    5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products;

    6 increased government pricing pressures;

    7 interruptions in production;

    8 loss of or inability to obtain adequate protection for intellectual property rights;

    9 litigation;

    10 loss of key executives or other employees; and

    11 adverse publicity and news coverage.

    Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to

    mean that Roches earnings or earnings per share for this year or any subsequent period will necessarily

    match or exceed the historical published earnings or earnings per share of Roche.

    For marketed products discussed in this presentation, please see full prescribing information on our website

    www.roche.com

    All mentioned trademarks are legally protected.

  • 4

    Group Severin Schwan Chief Executive Officer

  • YTD Sept 2017 performance

    Outlook

    5

  • YTD Sept 2017: Strong sales growth in both

    divisions

    6 CER=Constant Exchange Rates

    2017 2016

    CHFbn CHFbn CHF CER

    Pharmaceuticals Division 30.6 29.1 5 5

    Diagnostics Division 8.8 8.4 5 5

    Roche Group 39.4 37.5 5 5

    Change in %

  • YTD Sept 2017: Strong sales growth in US and

    International

    7

    0

    2

    4

    6

    8

    10

    12

    14

    16

    18

    Japan International Europe US

    Diagnostics

    Pharma

    CHFbn

    +10%

    -2% +4%

    +2%

    +1% +14%

    +1%

    -1%

    +8%

    -1%

    +2%

    +7%

    All growth rates at Constant Exchange Rates (CER)

  • Q3 2017: Sales growth for the sixth consecutive

    year

    8

    2%

    6%

    4%

    6% 6%

    4%

    8%

    7%

    5%

    4%

    5%

    6%

    5%

    7%

    6%

    4% 4%

    6%

    3% 3%

    4%

    6% 6%

    0%

    2%

    4%

    6%

    8%

    10%

    Q1

    12

    Q2

    12

    Q3

    12

    Q4

    12

    Q1

    13

    Q2

    13

    Q3

    13

    Q4

    13

    Q1

    14

    Q2

    14

    Q3

    14

    Q4

    14

    Q1

    15

    Q2

    15

    Q3

    15

    Q4

    15

    Q1

    16

    Q2

    16

    Q3

    16

    Q4

    16

    Q1

    17

    Q2

    17

    Q3

    17

    All growth rates at Constant Exchange Rates (CER)

  • YTD Sep 2017: Successful launch activities

    Differentiation driving growth

    9

    EU: Positive CHMP opinion in 1L ALK+ NSCLC

    US: 1L under FDA priority review and listing in NCCN

    guidelines as category 1 preferred option

    EU approval in bladder (1/2L) & lung (2L)

    Approved in RMS & PPMS: US, CH, Australia

    Positive early feedback from all stakeholders

    Additional sales

    of recent launches

    +900m

    Ocrevus

    +500m

    Alecensa

    +122m

    Tecentriq

    +278m

    CHF

    PPMS=primary progressive multiple sclerosis; RMS=relapsing forms of multiple sclerosis; NCCN=National Comprehensive Cancer Network;

    CHMP=Committee for Medicinal Products for Human Use

    Total:

  • Q3 2017: Sustainable Roche business case

    Important milestones achieved

    10

    HER2 franchise Perjeta in adjuvant BC (APHINITY) US priority review, EU filed

    CD20/Hematology

    Gazyva in 1L iNHL (GALLIUM)

    Venclexta in R/R CLL (MURANO)

    Polatuzumab in R/R DLBCL (Ph II)

    US priority review, EU approved

    Ph 3 met primary endpoint

    BTD, EU PRIME designation

    Cancer Immunotherapy Tecentriq EU approved in bladder and lung

    Lung cancer Alecensa in 1L ALK+ NSCLC US priority review, positive CHMP opinion

    Hemophilia A Emicizumab in inhibitors

    (HAVEN 1 and 2)

    BTD, US priority review, EU accelerated

    assessment

    Neuroscience Ocrevus Additional approvals in AUS, CAN, CH

    Spinal Muscular Atrophy SMN2 splicer (SUNFISH) Ph 1b at WMS* Pivotal Ph III initiated

    * WMS=World Muscle Society, October 2017; BTD=breakthrough therapy designation

  • Roche significantly advancing patient care

    Recognition for innovation 2013-present

    11

    Rank Company #

    1 Roche 18

    2 Novartis 15

    3 BMS 10

    4 Merck 9

    4 Pfizer 9

    18 Breakthrough Therapy Designations

    Source: http://www.focr.org/breakthrough-therapies as of October 2017; BR=bendamustin+Rituxan; DLBCL=diffuse large B cell lymphoma; LDAC=low dose cytarabine;

    AML=acute myeloid leukemia; ECD=Erdheim-Chester disease; NSCLC=non-small cell lung cancer; PPMS=primary progressive multiple sclerosis; HMA=hypomethylating

    agent; CLL=chronic lymphocytic leukemia; IPF=idiopathic pulmonary fibrosis

    http://www.focr.org/breakthrough-therapieshttp://www.focr.org/breakthrough-therapieshttp://www.focr.org/breakthrough-therapies

  • YTD Sept 2017 performance

    Outlook

    12

  • Aiming to set new standards of care

    Upcoming readouts for CIT & Hematology

    13

    Readouts:

    (Q4 17 to Q2 18)

    Most comprehensive lung cancer program

    addressing all common backbones Lung

    5 trials in non-squamous,

    squamous & small cell

    lung cancer

    Among the leaders in renal cancer GU 1L RCC

    First-in-class in colorectal cancer CRC 2/3L CRC

    First-in-class in triple negative breast cancer Breast 1L TNBC

    First-in-class in non-inhibitor hemophilia A Hemophilia Non-inhibitors and

    monthly schedule

  • Launch of new medicines at a record high

    2011 2012 2013 2014 2015 2016 2017

    Emicizumab

    (filed)

    14

  • 2017 outlook raised at HY

    15

    Group sales growth1 Mid-single digit

    Core EPS growth1 Broadly in line with sales growth

    Dividend outlook Further increase dividend in Swiss francs

    1 At Constant Exchange Rates (CER)

  • 16

    Pharmaceuticals Division Daniel ODay CEO Roche Pharmaceuticals

  • YTD Sept 2017 sales

    Innovation

    Outlook

    17

  • YTD Sept 2017: Pharma sales

    Strong growth in US due to ongoing launches

    18 CER=Constant Exchange Rates

    2017 2016

    CHFm CHFm CHF CER

    Pharmaceuticals Division 30,636 29,140 5 5

    United States 15,266 13,850 10 10

    Europe 6,766 6,916 -2 -2

    Japan 2,675 2,690 -1 2

    International 5,929 5,684 4 4

    Change in %

  • YTD Sept 2017: Strong sales performance with

    increasing contribution from new launches

    19 Absolute values and growth rates at Constant Exchange Rates (CER)

    -250 -150 -50 50 150 250 350 450 550

    Tarceva

    Avastin

    Tamiflu

    Pegasys

    Lucentis

    Esbriet

    Activase/TNKase

    Herceptin

    Alecensa

    MabThera/Rituxan

    Actemra/RoActemra

    Xolair

    Perjeta

    Tecentriq

    Ocrevus

    US

    Europe

    Japan

    International-17%

    +357%

    +17%

    +17%

    +13%

    +102%

    +2%

    -2%

    -21%

    +14%

    CHFm

    -36%

    +11%

    +2%

    n/a

    +4%

  • 0 5 10

    Cotellic +

    Zelboraf

    Alecensa

    Tecentriq

    Tarceva

    CD20

    Avastin

    HER2

    Perjeta

    Herceptin

    Kadcyla

    +6%

    -2%

    -17%

    +357%

    +3%

    Gazyva/Gazyvaro

    Cotellic

    MabThera/Rituxan

    (Oncology)

    -12%

    +102%

    20

    YTD Sept 2017: Oncology with +3% growth

    CHFbn

    YoY CER growth

    YTD Sept 2017 Oncology sales: CHF 19.2bn; All growth rates at Constant Exchange Rates (CER); CIT=cancer immunotherapy;

    FL=follicular lymphoma; NCCN=National Comprehensive Cancer Network

    Increased competition

    Breast cancer reimbursement in France,

    CIT competition in US

    Perjeta: Strong growth in all regions

    Kadcyla: Growth driven by International, US, and EU

    US: Cotellic+Zelboraf stable 1/2L market share

    EU: Cotellic+Zelboraf increasing; Zelboraf mono declining

    US: NCCN category 1 listing in 1L as preferred option

    US/EU: 1L filing completed (Positive CHMP opinion)

    EU: Approval in lung (2/3L) and bladder (2L and 1L

    cisplatin ineligible) achieved

    US: Gazyva in 1L FL (GALLIUM) on NCCN guidelines

    EU: Approval in 1L FL achieved

  • HER2 franchise: Growth driven by Perjeta and

    Kadcyl

Search related